RWD131 COST-EFFECTIVENESS OF DOSTARLIMAB PLUS CHEMOTHERAPY FOR PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER FROM TAIWAN’S NATIONAL HEALTH INSURANCE PERSPECTIVE
Abstract
Authors
Chi-Yun Wu Hsiao-Tung Tsai Yi Wen Chang Fei-Yuan Sharon Hsiao Chyong-Huey Lai Yao-Chun Wen Shih-Tsung Huang Liang-Yi Lin